Here's why the ResMed share price is charging higher today

ResMed shares have been given a boost…

| More on:

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The ResMed Inc (ASX: RMD) share price has been a positive performer on Thursday.

In morning trade, the sleep treatment company's shares are up almost 2% to $34.08.

This means the ResMed share price is now up 20% over the last two months.

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.

Image source: Getty Images

What's driving the ResMed share price higher?

Investors have been buying the company's shares today following a strong night for its NYSE-listed shares.

ResMed's shares rose almost 5% on Wall Street last night after the US FDA issued a recall for rival Philips' masks used with bilevel positive airway pressure machines and continuous positive airway pressure (CPAP) machines.

The regulator notes that the recalled mask can cause potential injuries or death when use with magnets interferes with certain implanted metallic medical devices and metallic objects in the body. Worryingly, it isn't just the user of the mask that is at risk. The FDA statement explains:

The recalled masks have magnets (placements shown by black circles in the picture below) and can cause potential injuries or death when use of a recalled mask with magnets interferes with certain implanted metallic medical devices and metallic objects in the body. These potential adverse events can occur in people who use the masks, or in people near a person using the mask. Additionally, the recalled Philips masks may be used with other manufacturers' BiPAP and CPAP machines.

Broker responds to the news

A number of brokers have responded positively to this news, giving the ResMed share price an additional boost.

Credit Suisse and Macquarie have both released bullish notes suggesting that this could lead to market share gains for ResMed.

In response, Macquarie has retained its outperform rating and $38.70 price target and Credit Suisse has retained its outperform rating with a $40.00 price target.

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has positions in and has recommended ResMed Inc. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has recommended ResMed. The Motley Fool Australia has positions in and has recommended ResMed Inc. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Healthcare Shares

Falling pills in a blue background.
Healthcare Shares

This ASX healthcare company's profit has rocketed 24%

Expansion into new markets is paying off.

Read more »

Doctor checking patient's spine x-ray image.
Healthcare Shares

Are these rocketing ASX healthcare shares a must buy?

These companies all rose significantly to start the week.

Read more »

A doctor and an elderly couple sit at a desk and look at a lung scan uploaded.
Healthcare Shares

Why did 4DMedical shares charge higher today, then drop?

The company's key technology has received a big tick.

Read more »

Business woman working from home with stock market chart showing percent change on her laptop screen.
Healthcare Shares

Should I invest $10,000 in CSL shares before the end of May?

This ASX healthcare giant has fallen hard, but the lower price and improving dividend appeal make it worth another look.

Read more »

A woman wakes up after sleeping soundly, stretching her arms high sitting in bed.
Healthcare Shares

Why this fallen ASX 200 blue chip could be a strong buy

I think the market may be underestimating the durability of this healthcare business.

Read more »

Female pharmacist smiles with a digital tablet.
Broker Notes

3 reasons to buy Sigma Healthcare shares today

A leading analyst expects “impressive growth” from Sigma Healthcare shares.

Read more »

A young woman lifts her red glasses with one hand as she takes a closer look at news.
Healthcare Shares

Could this fallen ASX 200 stock be a once-in-a-decade opportunity?

The valuation now looks far more interesting for a healthcare stock with a global leadership position.

Read more »

Hand dropping a mic.
Healthcare Shares

Pro Medicus shares jump as massive US contract win turns heads

Pro Medicus shares are rocketing after a major US win.

Read more »